semaglutide and heart failure Semaglutide in Patients With Obesity and Heart Failure Across Mildly Reduced or Preserved Ejection Fraction

Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials

20.93

★★★★☆4.8 (126)

In patients with heart failure with preserved ejection fraction and obesity, but without type 2 diabetes, semaglutide treatment has led to larger reductions in heart failure–related symptoms and physical limitations and greater

20.61

★★★★★4.9 (98)

In patients with cardiometabolic #HFpEF, #semaglutide and #tirzepatide reduced the risk of hospitalization for heart failure or all-cause mortality compared to sitagliptin, but tirzepatide offered no additional benefit over semaglutide. https://ja.ma

29.70

★★★★★5.0 (157)

Semaglutide may reduce heart events more than tirzepatide

24.18

★★★★★4.7 (84)

Impact of semaglutide on health outcomes and mood in obese heart failure patients: a retrospective analysis | Clinical Research in Cardiology

27.67

★★★★★4.9 (203)

𝙎𝙏𝙀𝙋-𝙃𝙁𝙥𝙀𝙁 𝙏𝙧𝙞𝙖𝙡 #CCU_TRAIL 𝐒𝐞𝐦𝐚𝐠𝐥𝐮𝐭𝐢𝐝𝐞 𝐢𝐧 𝐏𝐚𝐭𝐢𝐞𝐧𝐭𝐬 𝐰𝐢𝐭𝐡 𝐇𝐞𝐚𝐫𝐭 𝐅𝐚𝐢𝐥𝐮𝐫𝐞 𝐰𝐢𝐭𝐡 𝐏𝐫𝐞𝐬𝐞𝐫𝐯𝐞𝐝 𝐄𝐣𝐞𝐜𝐭𝐢𝐨𝐧 𝐅𝐫𝐚𝐜𝐭𝐢𝐨𝐧 𝐚𝐧𝐝 𝐎𝐛𝐞𝐬𝐢𝐭𝐲 ©️Published August 25, 2023 𝙄𝙣 𝙖𝙙𝙪𝙡𝙩𝙨

23.95

★★★★★5.0 (176)

Impact of Semaglutide 2.4 mg on Healthcare Resource Utilization and Medical Costs in Patients With Heart Failure in the United States (SHINE-HF)

29.78

★★★★★4.8 (132)